Hyperparathyroidism primary prevention: Difference between revisions
Created page with "__NOTOC__ {{Hyperparathyroidism}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {..." |
m Bot: Removing from Primary care |
||
| (7 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{Hyperparathyroidism}} | {{Hyperparathyroidism}} | ||
{{CMG}}; {{AE}} {{Anmol}} | |||
==Overview== | |||
Effective measures for the [[Prevention (medical)|primary prevention]] of secondary hyperparathyroidism in [[Chronic renal failure|chronic kidney disease]] include aggressive management of [[hyperphosphatemia]] in early stages of [[Chronic renal failure|chronic kidney disease]] and prevention and treatment of [[vitamin D deficiency]] in stage 3 & 4 [[chronic kidney disease]]. There are no established measures for the [[primary prevention]] of primary hyperparathyroidism and tertiary hyperparathyroidism. | |||
==Primary Prevention== | |||
*Effective measures for the primary prevention of secondary hyperparathyroidism in [[Chronic renal failure|chronic kidney disease]] include:<ref name="pmid14520607">{{cite journal| author=National Kidney Foundation| title=K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. | journal=Am J Kidney Dis | year= 2003 | volume= 42 | issue= 4 Suppl 3 | pages= S1-201 | pmid=14520607 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14520607 }} </ref> | |||
**Aggressive management of [[hyperphosphatemia]] in early stages of [[chronic kidney disease]]. | |||
**Prevention and treatment of [[vitamin D deficiency]] in stage 3 & 4 [[Chronic renal failure|chronic kidney disease]]. | |||
*There are no established measures for the [[primary prevention]] of primary hyperparathyroidism and tertiary hyperparathyroidism. | |||
==References== | ==References== | ||
{{Reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Disease]] | |||
[[Category: | [[Category:Medicine]] | ||
[[Category:Endocrinology]] | |||
[[Category:Parathyroid disorders]] | [[Category:Parathyroid disorders]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
Latest revision as of 22:16, 29 July 2020
|
Hyperparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hyperparathyroidism primary prevention On the Web |
|
American Roentgen Ray Society Images of Hyperparathyroidism primary prevention |
|
Risk calculators and risk factors for Hyperparathyroidism primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Effective measures for the primary prevention of secondary hyperparathyroidism in chronic kidney disease include aggressive management of hyperphosphatemia in early stages of chronic kidney disease and prevention and treatment of vitamin D deficiency in stage 3 & 4 chronic kidney disease. There are no established measures for the primary prevention of primary hyperparathyroidism and tertiary hyperparathyroidism.
Primary Prevention
- Effective measures for the primary prevention of secondary hyperparathyroidism in chronic kidney disease include:[1]
- Aggressive management of hyperphosphatemia in early stages of chronic kidney disease.
- Prevention and treatment of vitamin D deficiency in stage 3 & 4 chronic kidney disease.
- There are no established measures for the primary prevention of primary hyperparathyroidism and tertiary hyperparathyroidism.
References
- ↑ National Kidney Foundation (2003). "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease". Am J Kidney Dis. 42 (4 Suppl 3): S1–201. PMID 14520607.